Olema Oncology announced the appointment of Sandra J. Horning, M.D., FACP, FASCO, to the company's Board of Directors. Dr. Horning retired from Roche in 2019 after a 10-year career at Roche/Genentech during which she helped bring 15 new medicines to patients including in oncology. She most recently served as Chief Medical Officer and Global Head of Product Development. Dr. Horning is currently a co-founder of and advisor to EQRx, a biotechnology company focused on creating innovative medicines at lower prices. She serves on the Board of Directors of Gilead Sciences and Moderna.